Disclosed is a phenyl substituted triazole for formula (V) where the substituents are as disclosed in the description. Examples of compound of formula (V) are: 4-(4-(2,3-dihydro-1H-inden-5-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-5-hydroxy-2-isopropylphenyl dihydrogen phosphate 5-hydroxy-4-(5-hydroxy-4-(6-morpholinopyridin-3-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate and 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate. Also disclosed is the use of a compound of formula (V) for the preparation of a medicament for use in: (i) inhibiting Hsp90 in a cell (ii) treating or preventing proliferative disorder in a mammal (iii) treating cancer in a mammal (iv) inducing degradation of a c-kit protein, a Bcr-Abl protein, a FLT3 protein, or an EGFR protein (v) treating a c-kit associated cancer, a Bcr-Abl associated cancer, a FLT3 associated cancer, or an EGFR associated cancer in a mammal (vi) treating or inhibiting angiogenesis in a subject in need thereof (vii) blocking, occluding, or otherwise disrupting blood flow in neovasculature (viii) treating a non-Hodgkins lymphoma (ix) treating or preventing a fungal infection, a bacterial infection, a viral infection, or a parasitic infection in a subject (x) inhibiting topoisomerase II in a subject (xi) modulating the activity of glucocorticoid receptors in a cell (xii) treating or preventing an inflammatory disorder in a subject (xiii) treating or preventing an immune disorder in a subject or (xiv) suppressing the immune system in a subject in need thereof. Further disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (V).
